HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Bullfrog Kids UV Defender will be supported with print ads in parenting magazines coinciding with the product's launch early next year, Chattem reports during first annual investor call Nov. 11. Bullfrog Kids is debuting alongside three other new Bullfrog products, including a Surfer Gel (1"The Rose Sheet" Sept. 27, 2004, p. 6). Chattem also will support Bullfrog's other new products with radio ads intended to reach active adults and print ads to reach mothers, the firm notes. New skin care line ph20 by pHisoderm, which also is shipping in the first quarter, will initially roll out to about 2,800 stores nationwide, according to Chattem...

You may also be interested in...



Chattem Leaps Into 2005 With BullFrog, Phisoderm Extensions

Chattem is aiming to revitalize the pHisoderm brand with the launch of a new skin care line,pH20 by pHisoderm, early next year, the firm said

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel